COPENHAGEN, Denmark I June 18, 2025 I Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development ...

BOSTON, MA, USA and SHANGHAI, China I June 18, 2025 I Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule ...

HONG KONG, China I June 19, 2025 I Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to ...

CAMBRIDGE, MA, USA I June 18, 2025 I Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The ...

Combination of World Leading Epitranscriptomics and AI-Driven Automation Aims to Accelerate Development of Cancer Therapies That Halt Metastasis ...

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease ...

PHILADELPHIA, PA, USA I June 17, 2025 I Integral Molecular, the industry leader in discovering antibodies against membrane proteins, is pleased to announce ...

Clinical validation of stem cell reactivation approach positions Pelage as leader in regenerative medicine and aging ...

SKY-0515 is an oral small molecule designed to reduce the production of both huntingtin (HTT) and PMS1 proteins—two key drivers of HD pathology ...

Interim data on the cancer treatment shows robust potential for balancing efficacy and safety. TAIPEI, Taiwan and SHANGHAI, China and SAN FRANCISCO, CA, USA I June 17, 2025 I Foll ...

SANTIAGO DE COMPOSTELA, Spain & SHANGHAI, China I June 17, 2025 I SunRock Biopharma and Escugen have joined forces in a strategic partnership to ...

I Orion Corporation and Glykos Finland Oy today announced that they have extended their research collaboration and licensing agreement for the ...